Impact of Radiotherapy on Survival in Breast Cancer Patients
June 3, 2026 updated by: Fereshteh Abbasvandi, Motamed Cancer Institute
Impact of Radiotherapy on Disease-Free and Overall Survival in Breast Cancer Patients: A Retrospective Cohort Study
In this study, using a large retrospective cohort, the investigators evaluate the impact of RT on disease-free survival and overall survival of patients with BC.
The aim is to determine the true role of radiotherapy in improving patient outcomes and to provide a basis for designing more precise treatment strategies in the future.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
1030
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
BC patients diagnosed between January 1998 and February 2008 were identified from prospectively maintained breast cancer registries in the Motamed Breast Cancer Research in Tehran, Iran.
Description
Inclusion Criteria:
-BC patients diagnosed between January 1998 and February 2008 in the Motamed Breast Cancer Research in Tehran, Iran.
Exclusion Criteria:
- Male patients.
- Patients with missing LPFS and OS information (zero encounter/follow-up).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Breast Cancer Patients who underwent RT
|
Radiotherapy after BCS surgery in accordance to standard breast cancer guidelines
|
|
Breast Cancer Patients who did not underwent RT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Survival
Time Frame: 25 years
|
25 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 1998
Primary Completion (Actual)
February 1, 2008
Study Completion (Actual)
January 1, 2025
Study Registration Dates
First Submitted
May 28, 2026
First Submitted That Met QC Criteria
June 3, 2026
First Posted (Actual)
June 8, 2026
Study Record Updates
Last Update Posted (Actual)
June 8, 2026
Last Update Submitted That Met QC Criteria
June 3, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IR.SUMS.REC.1405.141
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.